Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

Just three months after Daniel O'Day took the helm, Gilead has pulled the trigger on adding targeted protein degradation to its modality tool kit in areas it has tagged as growth drivers. Wednesday’s announcement of a deal with Nurix came after Gilead had seen enough preclinical validation for the therapeutic class and found a partner it thinks provides more options for tissue-specific degradation than competitors, Gilead SVP of Biology Linda Higgins told BioCentury.

Gilead Sciences Inc. (NASDAQ:GILD) partnered with Nurix Therapeutics Inc. (San Francisco, Calif.) to identify targeted

Read the full 872 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE